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RAPID COMMUNICATION
A specific endothelin subtype A receptor antagonist protects
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A specific endothelin subtype A receptor antagonist protects against
injury in renal disease progression. We have recently reported that renal
preproendothelin-1 gene is up-regulated in rats with renal mass reduc-
tion (RMR) and that time-dependent increase in urinary excretion of the
corresponding peptide correlates with renal disease progression. Here
we evaluated whether a specific endothein subtype A (ETA) receptor
antagonist, PR139317, reduced signs of disease activity in this model.
Two groups of rats were given FR139317 or its vehicle (saline) from day
7 to day 60 after the surgical procedure. Sham-operated animals were
the control group. Blood pressure, urinary protein excretion and serum
creatinine were evaluated at days 0, 7 (before FR139317 or saline
administration), 30, 45 and 60. At sacrifice, histological evaluation of
renal tissue was performed. The results showed that ETA receptor
blocker reduced the abnormal permeability to proteins, limited glomer-
ular injury and prevented renal function deterioration thus confirming
the working hypothesis. These findings suggest that this class of
compounds may eventually prove useful in the treatment of human
progressive nephropathies.
Most human renal diseases progress to end-stage renal insuf-
ficiency even independently from the initial insult. This is
particularly true for diseases which manifest with increased
glomerular permeability to macromolecules. The fact that until
recently no treatments were available to slow their progression
has stimulated animal research to identify potential drugs with
renoprotective properties. Most of these studies have been
done in rats. The kidney's adaptive response to surgical reduc-
tion in nephron number was used as a condition close enough to
the pathophysiology of renal disease progression in humans. In
this model, soon after surgery systemic hypertension develops
together with loss of selective properties of the glomerular
barrier, both of which precede glomerular structural injury [1,
2]. In previous studies we have documented an up-regulation of
renal endothelin-l gene expression in this model which paral-
leled the increased urinary excretion of the corresponding
protein [3, 4]. On account of its vasoactive [5] and mesangio-
proliferative properties [61 increased renal endothelin could
serve as a mediator of progression of renal injury. To verify
such a possibility, we tested whether a molecule that specifi-
cally binds to the endothelin subtype A receptor [7] protected
rats with remnant kidney against renal functional and structural
damage.
Methods
Experimental design
Male Sprague-Dawley rats (Charles River Italia S.p.a.,
Calco, Italy) weighing 275 to 300gat the start of the experiment
were used in these studies. All animals were allowed free access
to standard rat laboratory diet containing 20% protein by
weight, and tap water. Fifteen animals underwent right ne-
phrectomy and ligation of two or three branches of the left renal
artery (RMR) under ether anesthesia according to Olson et al
[8]. All rats survived and were followed for 60 days. Seven days
after renal ablation, RMR rats were divided into two groups:
Group I (N = 7) was given a specific ETA receptor antagonist,
FR1 39317 car-
bonyl]amino-4-mcthylpentanoyl]amino-3-[3 -(1 -methyl- 1H -in-
dolyl)]propionyl]amino-3-(2-pyridyl)propionic acid)] (Fujisawa
Pharmaceutical Co., Ltd., Osaka, Japan) [7] daily and intraperi-
toneally (i.p.) at a dose of 32 mg/kg for 53 days. FR139317
specifically binds ETA receptor binding sites, as documented in
vitro by concentration-dependent inhibition of the binding of
labeled ET-l to porcine and human aortic microsomes with an
IC50 in the nanomolar range [9]. This compound showed low
affinity (IC50 in micromolar concentrations) for ET-l specific
binding sites in porcine brain [9]. In viva a single bolus dose of
FR1 39317 completely inhibited the pressor response to ET-l,
but had no effect on the initial depressor response due to ET-3
in conscious normotensive rats [9]. Group 2 (N = 8) was given
daily i.p. saline (vehicle) for 53 days. An additional group of
eight rats was subjected to sham operation and monitored for 60
days.
In all groups of rats systolic blood pressure, proteinuria, and
serum creatinine were measured on days 0 (basal), 7 (before 32
mg/kg FR139317 or saline administration) and 30, 45, 60 days
after surgery. Animals were sacrificed by ether anesthesia at
day 60; kidneys were excised and renal tissue processed for
mRNA extraction and histological evaluation.
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Systolic blood pressure
Systolic blood pressure was recorded by tail plethysmogra-
phy in the conscious rats [10].
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Urinary protein excretion
Proteinuria was determined in 24 hour urines by the modified
Coomassie blue G-dye binding assay for proteins with bovine
serum albumin as standard [11].
Serum creatinine
Blood was collected from the tail vein of anesthetized ani-
mals. Serum was obtained after whole blood clotting and kept
frozen at —20°C until assayed. Creatinine was measured by
alkaline picrate method [12].
c-fos protooncogene gene expression
At sacrifice, renal tissue from RMR animals was pooled
together and mRNA extracted as previously reported [3].
Mouse c-fos cDNA inserted into pBR322 plasmid (ATCC,
Rockville, Maryland, USA) was labeled by nick-translation
method. Membranes were hybridized with 32P-labeled c-fos
probe and with rat GAPDH cDNA, taken as internal standard
of equal loading of the samples on the membrane, and exposed
to X-ray film for autoradiography. Differential expression in
RMR as compared with sham-operated animals was calculated
using densitometric analysis.
Histopathology
At sacrifice, renal tissue was obtained from all animals and
processed for light microscopy [13]. Mesangial hypercellularity
was graded from 0 to 3 by a semi-quantitative score (0, no
changes; 1, mild; 2, moderate; 3, severe hypercellularity). For
each animal, at least 150 glomeruli were examined and the
percentage of glomeruli presenting focal or global glomerulo-
sclerosis was determined. Tubular (atrophy, cast, and dilata-
tion) and interstitial changes (fibrosis and inflammation) were
graded from 0 to 4 (0, no changes; 1, changes affecting less than
25% of the sample; 2, changes affecting 25 to 50% of the sample;
3, changes affecting 50 to 75% of the sample; 4, changes
affecting 75 to 100% of the sample) [131. All renal biopsies were
analyzed by the same pathologist who was unaware of the
nature of the experimental groups.
Statistical analysis
Results are expressed as mean SE. Data were analyzed by
between-within analysis of variance (ANOVA) and differences
between individual groups assessed by the Tukey-Cicchetti test
for multiple comparisons. Estimates of renal damage by mor-
phological studies were compared with Mann-Whitney test.
The statistical significance level was defined as P < 0.05.
Results
Effect of FR139317 on systolic blood pressure
Blood pressure was comparable in all animal groups before
the surgical procedure (Fig. 1). Mean values SE were: 120.5
7.9 mm Hg in RMR receiving vehicle; 138.0 1.3 mm Hg in
RMR given FR139317 and 125.8 2.7 mm Hg in sham-operated
animals. Seven days after surgery blood pressure rose signifi-
cantly in both groups of RMR with respect to sham rats (RMR
+ vehicle 164.0 8.6 mm Hg; RMR + FR139317 163.4 9.3
mm Hg vs. sham 130.3 4.5 mm Hg, P < 0.05). A further
significant increase (P < 0.01) over sham-operated animals was
observed at 30 days in RMR rats given vehicle (190.0 8.8 vs.
119.4 5.5 mm Hg). FR139317 therapy significantly prevented
the increase in blood pressure with values averaging 154.8 6.9
mm Hg (P < 0.05 vs. RMR receiving vehicle; Fig. 1), although
blood pressure values were still significantly (P < 0.01) higher
than sham-operated animals. Rats with RMR receiving vehicle
at 45 and 60 days had systemic hypertension (191.5 11.2 and
191.1 8.7 mm Hg). At these time intervals, the ET receptor
antagonist held blood pressure significantly lower (153.3 7.1
and 144.9 6.9 mm Hg, P < 0.01) than vehicle. The difference
from sham-operated rats was no longer significant (45 days
132.5 4.0 and 60 days 123.9 5.2 mm Hg; Fig. 1).
Effect of FR139317 on proteinuria
Urinary protein excretion on day 0 was comparable in the
three groups of animals and was on average 20.4 0.8 mg/day
(Fig. 2). Urinary protein excretion values for both groups of
animals with RMR were numerically but not significantly dif-
ferent from sham-operated rats on day 7 (RMR + vehicle 49.5
15.8; RMR + FR139317 69.6 22.1 vs. sham 17.2 0.7
mg/day). Proteinuria in RMR rats given vehicle increased with
time, the difference becoming significant (P < 0.01) from day 30
after surgery (173.5 46.4 vs. sham 18.4 0.7 mg/day) and
increasing further thereafter (45 days 200.9 43.0 vs. sham 21.4
0.9, and 60 days 288.7 72.1 vs. sham 24.7 1.0 mg/day).
FR139317 significantly reduced proteinuria in RMR rats (30
days 67.7 19.4, P <0.05; 45 days 67.2 14.7, P < 0.01; 60
days 115.0 20.8, P < 0.01, mg/day; Fig. 2).
Effect of FR13931 7 on serum creatinine
Serum creatinine was significantly (P < 0.05) higher in RMR
than in sham-operated rats at seven days (1.47 0.15 vs. 0.62
0.01 mg/dl) and remained so thereafter (RMR: day 30, 1.37
0.09; day 45, 1.40 0.09; day 60, 1.49 0.10 mg/dl. Sham: day
30, 0.66 0.03; day 45, 0.72 0.02; day 60, 0.73 0.02 mg/dl;
P < 0.01). FR139317 significantly lowered serum creatinine
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Fig. 1. Time course of systemic blood pressure in rats with renal mass
reduction (RMR) receiving FR139317 (32 mg/kg) (N = 8, E) or vehicle(N = 7, •) and in sham-operated (N =8, •) animals. Data are mean
SE. OP < 0.05, A P < 0.01 versus sham at corresponding time; * P
< 0.05, ** P < 0.01 versus RMR receiving vehicle at corresponding
time.
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concentrations in RMR animals given the ET receptor antago-
nist (day 30, 1.05 0.03; day 45, 1.15 0.03; day 60, 1.14
0.04 mgldl) as compared to untreated RMR rats for each time
point considered (P < 0.05).
Effect of FR13931 7 on c-fos proto-onco gene gene expression
C-fos proto-oncogene gene expression normally precedes cell
proliferation and is known to be one of the earliest genomic
responses to cell stimulation by serum and growth factors [141.
Figure 3 shows that c-fos mRNA increased markedly in renal
tissue of animals with RMR studied 60 days after surgery
compared to sham-operated animals. C-fos mRNA levels in
RMR rats given ET receptor antagonist were decreased by 50%
with respect to RMR animals receiving vehicle (Fig. 3).
Effect of FR13931 7 on renal injury
At the end of the 60-day observation period our untreated rats
showed mesangial hypercellularity, and focal and segmental
glomerulosclerosis present on average in 41% (range 10 to 80%)
of glomeruli (Table 1, Fig. 4). These animals also showed
collapse of capillaries, hyaline deposits and adhesion of the
glomerular tuft to the Bowman's capsule. Nonglomerular his-
tological abnormalities included tubular atrophy, cast formation
in the distal tubules, interstitial inflammation and fibrosis. By
contrast, the FR139317-treated animals were strikingly pro-
tected from glomerular structural injury as indicated by minimal
structural alterations, almost no evidence of mesangial hyper-
cellularity, and an average frequency of segmental glomerulo-
sclerosis only in 2% of the glomeruli (range 0 to 8%; Table I,
Fig. 4). Blocking ET receptor had no deleterious effect in these
animals which remained normal in appearance and behaved
normally.
Discussion
Here we have found that a specific endothelin subtype A
receptor antagonist administered to rats with reduction of renal
mass from days 7 to 60 reduced the abnormal permeability to
Sham RMR+ RMR+
vehicle FRi 39317
Fig. 3. Densitometric analysis of the autoradiography of c-fos proto-
oncogene expression in kidney homogenates from RMR rats receiving
vehicle or ETA receptor antagonist and sham-operated animals. The
optical density of autoradiographic signals was calculated as the ratio of
c-fos to GAPDH mRNA. The mRNA level of renal tissue from sham
rats was arbitrarily made equal to I, and the intensity of the transcripts
of RMR kidney was calculated relative to that number.
Glomeruli with
Mesangial sclerotic Tubulointerstitial
hypercellulanty changes % damage
score (range) (range) score (range)
RMR + FRl393l7 0.1 (0—l) 2 (0_g)b 0.2 (0_l)a(N=8)
RMR + vehicle 1.1 (1—2) 41 (10—80) 1.7 (1—3)(N=7)
proteins, limited glomerular injury and prevented renal function
deterioration. The data also showed that the ETA receptor
antagonist normalized systemic blood pressure throughout the
study. Since systemic hypertension has a negative impact on
renal disease progression [15, 161, the question arises whether
the effect on progressive renal injury was a consequence of the
antihypertensive action of the drug. However, it has been
clearly shown [17] that normalizing systemic blood pressure per
se is not enough to prevent renal disease progression in this
model. Thus some effect on the local determinants of renal
injury must be assumed to explain the renoprotective effect of
ETA receptor blocking [18, 19]. It was not the purpose of the
present communication to address whether the favorable effects
of the ETA receptor antagonist on renal functional and struc-
tural injury in this model were associated with a reduction of
glomerular capillary hypertension. It is reasonable to assume
that this could indeed be the case given the marked effect of the
drug of lowering systemic blood pressure. The important issue
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Fig. 2. Urinary protein excretion in rats with RMR given FR139317 (32
mg/kg) (LI) or vehicle (U) and in sham-operated (•) animals. Data are
mean SE. A P < 0.01 versus sham at corresponding time; * P < 0.05,
** P < 0.01 versus RMR receiving vehicle at corresponding time.
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Table 1. Pathological changes in rats with chronically given
FR139317 or vehicle
Data are reported as mean scores and mean percentages.
P < 0.01 and b p < 0.002 vs. RMR + vehicle
A*3
B
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Fig. 4. Histological analysis showing pathological changes in glomer-
uli of RMR rats. Micrographs showing periodic acid-Schiff staining of
glomeruli. A. Staining of the basement membrane and extracellular
matrix in sham-operated rat glomerulus. B. From a rat on day 60 after
surgical ablation of renal mass. This rat received ETA receptor antag-
onist vehicle. C. From an animal with RMR receiving FR139317. A
marked increase in extracellular matrix is seen in B. C shows the effect
of ETA receptor antagonist in preventing extracellular matrix accumu-
lation and glomerulosclerosis. Magnification x450.
of whether the endothelin antagonist corrects intraglomerular
capillary hypertension in this model will soon be addressed by
an ad hoc investigation. Besides its effect on renal microcircu-
lation ET is a potent inducer of mesangial cell proliferation, an
effect which is fully accounted for by ETA receptor stimulation
[20]. Specifically, ETA receptor-linked phosphoinositide hy-
drolysis acts as the signal event for up-regulation of phospho-
lipase C mediated c-fos and c-myc oncogenes [211. These
intracellular events are consistently associated with cell prolif-
eration [22, 23] and data are available that this system also
operates in mesangial cells [61. Findings that the ETA receptor
antagonist suppressed up-regulation of c-fos proto-oncogene
expression in rats with RMR offers a biochemical basis to
interpret its property of limiting mesangial cell proliferation and
preventing renal disease progression. Moreover, one can spec-
ulate that blocking ETA receptors would also limit the biological
consequences of ET-l-induced up-regulation of genes encoding
for extracellular matrix proteins [24], which would in turn
reduce a major component of glomerulosclerosis [25]. Since
FR139317 is a highly selective antagonist for ETA receptors,
one may conclude that such a subtype of receptors is primarily
involved in mediating the deleterious effect of endothelin on the
kidney. Given the fact that glomerular endothelial and mesan-
gial cells express ET8 receptors [26, 27], their potential role
cannot be excluded until control experiments could be per-
formed with the ETB specific antagonist. The present findings
may have major clinical implications. Compounds that block
the biological consequences of excessive renal ET may even-
tually prove useful as renoprotective agents because they
normalize systemic blood pressure while at the same time
suppressing specific pathways of renal injury. Such com-
pounds, soon available for human use, will hopefully offer a
new and exciting possibility for retarding the progression of
human nephropathies.
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